Sex: U
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Mild injection site pain and no interference with activity / Moderate injection site tenderness (tenderness with movement); Moderate injection site redness; Moderate injection site swelling; Moderate fever (101.3 to 102 °F); Mild fatigue and no interference with activity; Mild muscle pain and no interference with activity; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Headache and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity / Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling) and PYREXIA (Moderate fever (101.3 to 102 °F)) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity / Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling), PYREXIA (Moderate fever (101.3 to 102 °F)), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (Headache and no interference with activity). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity / Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling), PYREXIA (Moderate fever (101.3 to 102 °F)), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (Headache and no interference with activity) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Moderate fever (101.3 to 102 Degree F).     The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       Concomitant medication use information was not provided by reporter.  Patient had experienced malaise, vaccination site pain, vaccination site erythema, vaccination site swelling, pyrexia, headache, nausea, vomiting, fatigue and myalgia anytime during the 2 days after your COVID-19 vaccination, which occurred on Wednesday, Dec 20, 2023 and Thursday, Dec 21, 2023  The Database Subject ID was reported as 5470608.  The Health Authority Subject ID was reported as 82873-71471.  Treatment medication use information was not provided by reporter.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:Patient 57 out of 87